Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.50 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS1 | P29475 | 6/20 | 0.49 |
| ▸ | NOS3 | P29474 | 5/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 4/20 | 0.43 |
| ▸ | ARG1 | P05089 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL22118555 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL651583 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL17629209 | 0.98 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1790 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL6374054 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL288132 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL31663499 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL7928810 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1791 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL2411547 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12521322-B2 | Foaming oral care compositions | THE PROCTER & GAMBLE COMPANY (US) | 2026-01-13 | — | — | US | claimed |
| CN-119925464-A | Preparation process and application of compound preparation of dog kidney cistanche, epimedium and zinc arginine for tonifying kidney | 恢春丹生物科技(海南)有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119632148-A | Powder-free granular composite premixed feed and preparation method thereof | 丰县新中牧饲料有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-118496683-A | Scavenger composition for sulfur species | 伊诺弗斯公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240197578-A1 | Foaming Oral Care Compositions | PROCTER & GAMBLE (US) | 2024-06-20 | — | — | US | claimed |
| CN-118160928-A | Composition for promoting water supplementing and preparation method and application thereof | 南京盛德创赢生物科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-117887056-A | Toughening agent with heat stabilization function, preparation method thereof and application thereof in PVC (polyvinyl chloride) pipe | 浙江工业大学 | 2024-04-16 | — | — | CN | claimed |
| US-11944694-B2 | Foaming oral care compositions | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-02 | — | — | US | claimed |
| CN-112655846-B | Organic trace element composite package for shrimps and crabs as well as preparation method and application thereof | 长沙兴嘉生物工程股份有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116655500-A | Arginine zinc chelate and preparation method thereof | 长沙兴嘉生物工程股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-104853725-A | ORAL CARE COMPOSITIONS COMPRISING ZINC AMINO ACID HALIDES | COLGATE PALMOLIVE CO LTD | 2015-08-19 | — | — | CN | claimed |
| CN-104530986-A | Rosin organic acid metal salt resin with chemical structural characteristics and performances of acrylate metal salt resin and preparation method and application of rosin organic acid metal salt resin | OCEAN UNIV CHINA | 2015-04-22 | — | — | CN | claimed |
| US-20090285865-A1 | Palatable, solid oral formulations for male chemical sterilization | POLY-MED, INC. | 2009-11-19 | — | — | US | claimed |
| EP-1843822-A1 | AN EMULSION COMPOSITION FOR WET WIPES CONTAINING A NON-IRRITATING SKIN HEALTH BENEFIT INGREDIENT AND THE PROCESS FOR MAKING SAID WET-WIPES | The Procter and Gamble Company (US) | 2007-10-17 | — | — | EP | claimed |
| WO-2006083980-A1 | AN EMULSION COMPOSITION FOR WET WIPES CONTAINING A NON-IRRITATING SKIN HEALTH BENEFIT INGREDIENT AND THE PROCESS FOR MAKING SAID WET-WIPES | THE PROCTER & GAMBLE COMPANY (US) | 2006-08-10 | — | — | WO | claimed |
| US-20060171971-A1 | Composition for wet wipes containing a non-irritating skin health benefit ingredient and the process for making | THE PROCTER & GAMBLE COMPANY | 2006-08-03 | — | — | US | claimed |
| CN-1757409-A | Recipe of Wanshou capsule, and health-care function | TAIYUN SCIENCE CO LTD SHANGHAI (CN) | 2006-04-12 | — | — | CN | claimed |
| CN-1228303-C | Process for the transesterification of fats and/or oils of biological origin by means of alcoholysis | PETER SIEGFRIED (DE) | 2005-11-23 | — | — | CN | claimed |
| CN-1336234-A | Chinese medicine-hylonoma euphorbia for treating prostate disease | LI QUANCAI (CN) | 2002-02-20 | — | — | CN | claimed |
| CN-1327472-A | Process for the transesterification of fats and/or oils of biological origin by means of alcoholysis | PETER SIEGFRIED (DE) | 2001-12-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197578-A1 | Foaming Oral Care Compositions | FOS, STOM, UGCG | OTC 245/4885DDAH1 1706/4885NOS2 3544/4885 |
| US-11944694-B2 | Foaming oral care compositions | FOS, STOM, UGCG | OTC 245/4885DDAH1 1706/4885NOS2 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.